The overall mortality rate for patients with Aids is between 30-40 percent
An unacceptably high number of people continue to develop and die of Aids-related diseases across sub-Saharan Africa. They remain left out of the global HIV response without access to treatment that prevents Aids or the medical care they need, says international medical humanitarian organisation Médecins Sans Frontières / Doctors Without Borders (MSF).
In MSF’s briefing paper “Waiting isn’t Option: Preventing and Surviving Advanced HIV” , data from MSF-supported hospitals presented at the International Aids Society (IAS) Conference on HIV Science in Paris, highlights that in MSF-run and MSF-supported hospitals in Democratic Republic of Congo (DRC), Guinea, Kenya and Malawi, people arrive with such severe immune failure that overall mortality for patients presenting with Aids is between 30-40%. Almost one-third of those deaths occur within 48 hours.
The main causes of illness and death are due to treatment failure or interruption and late diagnosis leading to delayed treatment. Unlike in the early 2000s, when little treatment was available, more than 50% of AIDS admissions at referral hospitals supported by MSF had already started antiretroviral therapy (ART), with many showing clinical signs of treatment failure.
“Despite extensive access to anti-retrovirals, there has not been the expected drop in late-stage presentations of HIV in developing countries. What’s different is that among people admitted to hospitals, the majority are already diagnosed and many have been on treatment for several years. In Kenya, in Homa-Bay, where anti-retrovirals have been available for years, half of the patients hospitalised Aids cases show signs of treatment failure. We’re pushing to switch these patients to second-line antiretrovirals more rapidly,” says David Maman, MSF Epicentre epidemiologist.
At community level, MSF population surveys also show that a proportion of people living with Aids in communities in southern and eastern Africa remain untested and untreated. Around 10% of people living with HIV in districts of Malawi, Kenya and South Africa had Aids, of which 47% had never received testing or treatment.
“People are still being diagnosed late. We need new ways to detect those left out, early on, before they arrive at hospital in often fatal condition or die at home without ever receiving care. Stigma and lack of information still remain high, leading to delayed treatment or no testing and treatment at all. This illustrates the need to complement increased antiretroviral coverage at community level with improved care for those on treatment for years,” says Gilles van Cutsem, MSF HIV Advisor.
Clinicians, including from MSF, have increasingly voiced concern over the lack of attention and means going towards the prevention and treatment of Aids across Africa.
The World Health Organisation (WHO) yesterday issued its first ever guidelines for the treatment of Aids in low-resource settings.
Key interventions urgently needed to prevent and treat Aids include the rapid roll-out of “test and start”, CD4 baseline testing at ART initiation, routine viral load testing, point of care diagnostics for tuberculosis, improved treatment for cryptococcal meningitis, rapid switch to second-line ART for failing and advanced patients, and swift, effective and accessible treatment for opportunistic infections. MSF is also calling for models of care geared towards prevention, treatment and support for patients with AIDS, and free specialised hospital-based care free of charge for patients.
MSF also expressed its concern that the situation will only be exacerbated as funding for the global HIV response continues to stagnate. Anticipated cuts in US funding to the Global Fund (17%) and PEPFAR (11%) from 2018 onwards will see many countries facing further grant restrictions.
Shrinking funding envelopes and the need to preserve ART purchases will imperil community responses, including targeted testing and improved treatment literacy and adherence, while starving essential investments needed for health workers, laboratory and diagnostics.